-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus Pharmaceuticals appoints ex-Genentech research chief Andrew Chan to board

PUBT·04/23/2026 11:31:50
Listen to the news
Corvus Pharmaceuticals appoints ex-Genentech research chief Andrew Chan to board
  • Corvus Pharmaceuticals appointed Andrew C. Chan to its board of directors.
  • Chan most recently served as senior vice president, Research Biology at Genentech, where he led biological research across therapeutic areas during a 25-year career.
  • Corvus cited Chan’s immunology background as it advances soquelitinib and its ITK inhibition platform across immune and inflammatory diseases and cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230730PRIMZONEFULLFEED9695508) on April 23, 2026, and is solely responsible for the information contained therein.